WallStreetZenWallStreetZen

NASDAQ: PETS
Petmed Express Inc Stock

$4.11-0.11 (-2.61%)
Updated Apr 18, 2024
PETS Price
$4.11
Fair Value Price
$7.14
Market Cap
$86.92M
52 Week Low
$4.01
52 Week High
$16.18
P/E
-31.62x
P/B
0.87x
P/S
0.56x
PEG
N/A
Dividend Yield
14.6%
Revenue
$276.97M
Earnings
-$2.66M
Gross Margin
28.1%
Operating Margin
-1.13%
Profit Margin
-1%
Debt to Equity
0.73
Operating Cash Flow
$7M
Beta
0.68
Next Earnings
May 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PETS Overview

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.

Zen Score

Industry Average (20)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PETS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PETS ($4.11) is undervalued by 42.41% relative to our estimate of its Fair Value price of $7.14 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PETS ($4.11) is significantly undervalued by 42.41% relative to our estimate of its Fair Value price of $7.14 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PETS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more PETS due diligence checks available for Premium users.

Be the first to know about important PETS news, forecast changes, insider trades & much more!

PETS News

Valuation

PETS fair value

Fair Value of PETS stock based on Discounted Cash Flow (DCF)
Price
$4.11
Fair Value
$7.14
Undervalued by
42.41%
PETS ($4.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PETS ($4.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PETS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PETS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-31.62x
Industry
-2.68x
Market
41.33x

PETS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.87x
Industry
1.14x
PETS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PETS's financial health

Profit margin

Revenue
$65.3M
Net Income
-$2.0M
Profit Margin
-3.1%
PETS's Earnings (EBIT) of -$3.14M... subscribe to Premium to read more.
Interest Coverage Financials
PETS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$173.4M
Liabilities
$73.3M
Debt to equity
0.73
PETS's short-term assets ($95.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PETS's short-term assets ($95.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PETS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PETS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.6M
Investing
-$1.4M
Financing
-$15.0k
PETS's operating cash flow ($6.92M)... subscribe to Premium to read more.
Debt Coverage Financials

PETS vs Pharmaceutical Retailer Stocks

TickerMarket Cap1d %P/EP/B
PETS$86.92M-2.61%-31.62x0.87x
YI$84.94M+3.09%N/A-1.07x
BIMI$15.53M-5.10%-0.52x1.78x
MEDS$8.35M-2.12%-0.69x0.72x
LFLY$5.11M+6.73%-0.47x-0.41x

Petmed Express Stock FAQ

What is Petmed Express's quote symbol?

(NASDAQ: PETS) Petmed Express trades on the NASDAQ under the ticker symbol PETS. Petmed Express stock quotes can also be displayed as NASDAQ: PETS.

If you're new to stock investing, here's how to buy Petmed Express stock.

What is the 52 week high and low for Petmed Express (NASDAQ: PETS)?

(NASDAQ: PETS) Petmed Express's 52-week high was $16.18, and its 52-week low was $4.01. It is currently -74.6% from its 52-week high and 2.49% from its 52-week low.

How much is Petmed Express stock worth today?

(NASDAQ: PETS) Petmed Express currently has 21,148,692 outstanding shares. With Petmed Express stock trading at $4.11 per share, the total value of Petmed Express stock (market capitalization) is $86.92M.

Petmed Express stock was originally listed at a price of $8.38 in Apr 26, 1999. If you had invested in Petmed Express stock at $8.38, your return over the last 24 years would have been -50.93%, for an annualized return of -2.92% (not including any dividends or dividend reinvestments).

How much is Petmed Express's stock price per share?

(NASDAQ: PETS) Petmed Express stock price per share is $4.11 today (as of Apr 18, 2024).

What is Petmed Express's Market Cap?

(NASDAQ: PETS) Petmed Express's market cap is $86.92M, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Petmed Express's market cap is calculated by multiplying PETS's current stock price of $4.11 by PETS's total outstanding shares of 21,148,692.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.